clinical trial · NCT05952856
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
Merck Sharp & Dohme LLC·phase3·completed·n = 2,912
HypercholesterolemiaFamilial HypercholesterolemiaEnlicitide DecanoatePlacebo
brief summary
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.
started
Aug 10, 2023
primary completion
Jul 28, 2025
completion
Jul 28, 2025
last updated
Sep 10, 2025
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol